Physician profile
Anita L Nelson
NPI 1629009139
$529,618.72
in general payments reported to CMS, 2019-2025
16 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $35K · 2021: $52K · 2022: $32K · 2023: $106K · 2024: $100K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $235K · Travel and Lodging: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Honoraria: $9,600 · Food and Beverage: $9,588 · Consulting Fee: $9,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $235,200.00 |
| Travel and Lodging | $16,744.78 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,310.08 |
| Honoraria | $9,600.00 |
| Food and Beverage | $9,588.21 |
| Consulting Fee | $9,527.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $282,127.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $99,342.09 | 2019-2022 | |
| Organon LLC | $37,191.41 | 2021-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $26,805.82 | 2019-2024 | |
| Therapeuticsmd, INC. | $20,385.54 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $13,298.35 | 2019-2020 | |
| Agile Therapeutics, INC. | $13,150.00 | 2021 | |
| Pfizer INC. | $11,700.00 | 2021-2022 | |
| Myovant Sciences INC. | $10,867.89 | 2021-2022 | |
| American Regent | $8,742.76 | 2019 | |
| Exeltis, USA INC. | $3,352.09 | 2023 | Slynd |
| Coopersurgical, INC. | $2,655.41 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.